Clinical trials: Lymphoma, Malignant
Peripheral T-cell Lymphoma
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in…
- Trial name
- NCT01420679
- Testing
- Pralatrexate Injection
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 21 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Cutaneous T-Cell Lymphoma, Leukemia-Lymphoma, Adult T-Cell
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma.
- Trial name
- NCT00699296
- Testing
- Panobinostat (LBH589)
- Where
- 7 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Cancer, Adult Solid Tumor
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.
- Conditions
- Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
- Trial name
- NCT03061305
- Where
- 40 sites in United States
- Volunteers
- 58,213 people
- Sponsor
- Strata Oncology
Lymphoma, Non Hodgkin
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's…
- Trial name
- NCT01987505
- Testing
- Rituximab
- Where
- 39 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Hodgkin Lymphoma
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin]…
- Trial name
- NCT01712490
- Testing
- brentuximab vedotin, doxorubicin, bleomycin
- Where
- 215 sites in United States, Australia and 19 more
- Volunteers
- 1,334 people
- Sponsor
- Takeda
Cutaneous T Cell Lymphomas (CTCL), Mycosis Fungoides (MF)
Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
A single arm, open label, multi-center, phase 2 study to assess the safety and anti-tumor activity of ImmunoPulse IL-12® in participants with stage IB to IIIB mycosis fungoides.
- Trial name
- CTCL (NCT01579318)
- Testing
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OncoSec Medical Incorporated
Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
In the proposed study, NM-IL-12 will be evaluated as immunotherapy to increase antitumor efficacy against CTCL, while reducing skin-related toxicity, when combined with low-dose TSEBT therapy.
- Conditions
- Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sézary Syndrome
- Trial name
- NCT02542124
- Testing
- NM-IL-12 and TSEBT
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neumedicines Inc.
Ulcerative Colitis
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
The purpose of this study is to describe the long-term safety risks in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi.
- Trial name
- OPAL (NCT02808780)
- Where
- 63 sites in United States, Austria and 7 more
- Volunteers
- 535 people
- Sponsor
- Janssen Biotech, Inc.
Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin's Lymphoma (NHL) or relapsed Non-Hodgkin's lymphoma and have…
- Trial name
- NCT00168727
- Testing
- ibritumomab tiuxetan (Zevalin®)
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Biogen
Hodgkin Lymphoma
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur.
- Trial name
- NCT03646123
- Testing
- brentuximab vedotin, doxorubicin, vinblastine
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 255 people
- Sponsor
- Seagen Inc.
Allergic Rhinitis, Rhinoconjunctivitis
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
This is an observational prospective study to assess the tolerability and safety of treatment of SCIT Allergovac Poliplus polymerized in depot presentation.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- APOLO (NCT02844842)
- Testing
- Allergovac Poliplus
- Where
- 15 sites in Spain
- Volunteers
- 152 people
- Sponsor
- Roxall Medicina España S.A
Advanced Solid Tumor, Cutaneous T Cell Lymphoma
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
This is a first in human, open-label, dose escalation and expansion Phase I study of SIM1811-03 in adult patients with advanced tumors.
- Trial name
- NCT05781386
- Testing
- SIM1811-03 or in combination with Sintilimab injectiont
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Jiangsu Simcere Biologics Co., Ltd
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Non-Hodgkin's Lymphoma
A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to assess the tolerability, pharmacokinetics and antitumor effect of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT00389051
- Testing
- bendamustine hydrochloride
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- SymBio Pharmaceuticals
Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.
- Trial name
- NCT03372837
- Testing
- Rituximab
- Where
- 29 sites in Japan
- Volunteers
- 40 people
- Sponsor
- SymBio Pharmaceuticals
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- Conditions
- Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT05479994
- Testing
- BGB-11417
- Where
- 50 sites in China
- Volunteers
- 100 people
- Sponsor
- BeiGene
Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
The primary purpose of this study is to determine the differences in PFS for participants who have been receiving brigatinib as ALK inhibitor therapy for ALK+NSCLC compared to those participants receiving alectinib, ceritinib…
- Trial name
- NCT03546894
- Testing
- Brigatinib, Alectinib, Ceritinib
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Takeda
Diffuse Large-Cell Lymphoma
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
The purpose of this study is to compare the standard CHOP-R regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab to CPOP-R (same regimen, but substituting Doxorubicin with Pixantrone).
- Trial name
- RAPID (NCT00268853)
- Testing
- CPOP-R, CHOP-R
- Where
- 75 sites in United States, Canada and 3 more
- Volunteers
- 124 people
- Sponsor
- CTI BioPharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.